AR008060A1 - Una formulacion no acuosa de peptidos y un metodo para prepararla - Google Patents

Una formulacion no acuosa de peptidos y un metodo para prepararla

Info

Publication number
AR008060A1
AR008060A1 ARP970102967A ARP970102967A AR008060A1 AR 008060 A1 AR008060 A1 AR 008060A1 AR P970102967 A ARP970102967 A AR P970102967A AR P970102967 A ARP970102967 A AR P970102967A AR 008060 A1 AR008060 A1 AR 008060A1
Authority
AR
Argentina
Prior art keywords
peptides
preparing
water formulation
long periods
stable
Prior art date
Application number
ARP970102967A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR008060A1 publication Critical patent/AR008060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulaciones próticas no-acuosas estables compuesto péptidos. Estas formulaciones estables comprenden péptidos en solventes próticos no-acuosos.Ellos pueden ser almacenados a temperaturas elevadas por alrgos períodos de tiempo y sonespec ialmente útiles en dispositivos implantables de liberaciónpor largos períodos de liberación de droga.
ARP970102967A 1996-07-03 1997-07-02 Una formulacion no acuosa de peptidos y un metodo para prepararla AR008060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03

Publications (1)

Publication Number Publication Date
AR008060A1 true AR008060A1 (es) 1999-12-09

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102967A AR008060A1 (es) 1996-07-03 1997-07-02 Una formulacion no acuosa de peptidos y un metodo para prepararla

Country Status (27)

Country Link
EP (1) EP0909175B1 (es)
JP (3) JP2001504802A (es)
CN (1) CN1231256C (es)
AR (1) AR008060A1 (es)
AT (1) ATE241997T1 (es)
AU (1) AU737664B2 (es)
BR (1) BR9710130A (es)
CA (1) CA2259403A1 (es)
CO (1) CO4890854A1 (es)
CZ (1) CZ433898A3 (es)
DE (1) DE69722620T2 (es)
DK (1) DK0909175T3 (es)
ES (1) ES2201306T3 (es)
HU (1) HUP9903942A3 (es)
ID (1) ID19165A (es)
IL (1) IL127769A (es)
MY (1) MY121684A (es)
NO (1) NO323933B1 (es)
NZ (1) NZ333580A (es)
PL (1) PL189402B1 (es)
PT (1) PT909175E (es)
RO (1) RO119862B1 (es)
RU (1) RU2203085C2 (es)
SK (1) SK284490B6 (es)
TW (1) TW491703B (es)
WO (1) WO1998000152A1 (es)
ZA (1) ZA975942B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504802A (ja) * 1996-07-03 2001-04-10 アルザ コーポレイション 非水性プロトン性ペプチド配合物
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004031011D1 (de) * 2003-04-25 2011-02-24 Boston Scient Scimed Inc Feste arzneimittelformulierung und vorrichtung zu ihrer aufbewahrung und kontrollierten abgabe
PL1687019T3 (pl) * 2003-11-20 2018-05-30 Novo Nordisk A/S Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
WO2008089426A2 (en) * 2007-01-19 2008-07-24 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
LT2328601T (lt) 2008-08-15 2020-04-27 Ironwood Pharmaceuticals, Inc. Linaklotidą turinčios vaisto formos, skirtos vartoti per burną
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
MX340234B (es) 2010-02-17 2016-07-01 Ironwood Pharmaceuticals Inc Tratamiento para transtornos gastrointestinales.
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2846230A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
DE69312947T2 (de) * 1992-09-21 1998-01-08 Pharmacia & Upjohn Company Kal Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
JP2001504802A (ja) * 1996-07-03 2001-04-10 アルザ コーポレイション 非水性プロトン性ペプチド配合物

Also Published As

Publication number Publication date
DE69722620T2 (de) 2004-04-29
ATE241997T1 (de) 2003-06-15
JP2001504802A (ja) 2001-04-10
NZ333580A (en) 2000-06-23
HUP9903942A3 (en) 2000-07-28
IL127769A0 (en) 1999-10-28
NO323933B1 (no) 2007-07-23
AU3407397A (en) 1998-01-21
MY121684A (en) 2006-02-28
BR9710130A (pt) 1999-08-10
TW491703B (en) 2002-06-21
ZA975942B (en) 1998-04-16
CN1231256C (zh) 2005-12-14
JP2008195739A (ja) 2008-08-28
CN1224356A (zh) 1999-07-28
ES2201306T3 (es) 2004-03-16
SK284490B6 (sk) 2005-05-05
EP0909175A1 (en) 1999-04-21
EP0909175B1 (en) 2003-06-04
DE69722620D1 (de) 2003-07-10
ID19165A (id) 1998-06-28
PL330869A1 (en) 1999-06-07
PL189402B1 (pl) 2005-08-31
CO4890854A1 (es) 2000-02-28
PT909175E (pt) 2003-10-31
IL127769A (en) 2006-10-31
CA2259403A1 (en) 1998-01-08
RO119862B1 (ro) 2005-05-30
JP2010043105A (ja) 2010-02-25
NO986209D0 (no) 1998-12-30
HUP9903942A2 (hu) 2000-04-28
DK0909175T3 (da) 2003-09-29
NO986209L (no) 1998-12-30
SK179998A3 (en) 1999-05-07
WO1998000152A1 (en) 1998-01-08
CZ433898A3 (cs) 1999-04-14
RU2203085C2 (ru) 2003-04-27
AU737664B2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
AR008060A1 (es) Una formulacion no acuosa de peptidos y un metodo para prepararla
AR007714A1 (es) Una formulación no acuosa estable de un compuesto peptídico, y un método para preparar la formulación.
AR012448A1 (es) Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
MY125556A (en) Aqueous formulations of peptide
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
PT1197221E (pt) Preparacoes de g-csf estabilizadas a longo prazo.
AP2002002458A0 (en) Compounds for the treatment of ischemia.
IT1288257B1 (it) Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
FR2751875B1 (fr) Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
BG103425A (en) Pharmaceutical composition
BR0012429A (pt) Fórmulações para il-11
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
ES2087652T3 (es) Composiciones cosmeticas y/o farmaceuticas y metodos para su uso en proteger tejidos del contacto con metales pesados.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
ZA978099B (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance.
NO985145D0 (no) Farmas°ytiske preparater for forsinket frigj°ring av uoppl°selige, aktive bestanddeler
NO984920L (no) Preparater omfattende en nitronforbindelse for anvendelse ved behandling av okulµr inflammasjon
PT928192E (pt) Gel antimicotico com elevada libertacao de principio activo
IL136278A (en) Thermodynamically stable form of (r)-3-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic acid (ramatroban), process for its preparation and pharmaceutical compositions comprising it
PT1014951E (pt) Composicao de revestimento farmaceutica e metodo para a sua utilizacao
ES1026321Y (es) Anclaje para protesis dental removible.

Legal Events

Date Code Title Description
FB Suspension of granting procedure